EGFR and neoplasm: In this large retrospective clinicogenomic dataset, real-world progression-free and overall survival were significantly shorter among treated EGFR-mutated aNSCLC patients with a TP53 co-mutation versus those with a TP53 wild-type tumor, even after adjustment for known clinicopathologic prognostic factors.